Longitudinal changes in antipsychotic dose in patients treated with long-acting injectable second-generation antipsychotics. 2021

Nozomi Nakajima, and Nao Mizoe, and Fuminari Misawa, and Toru Yamashita, and Ryuhei So, and Kohei Kitagawa, and Kenichi Tanimoto, and Yoshiki Kishi, and Yasuo Fujii, and Hiroyoshi Takeuchi
Yamanashi Prefectural Kita Hospital, Yamanashi.

Only a few studies have investigated changes in the dose of long-acting injectable second-generation antipsychotics (LAI-SGAs) over the long term in the maintenance treatment of schizophrenia. In this retrospective cohort study, we examined longitudinal changes in antipsychotic dose over a 3-year period in patients with schizophrenia who had been taking LAI-SGAs for at least 1 year. We compared the total daily chlorpromazine equivalent dose of antipsychotics at 12, 24 and 36 months with the baseline dose at 3 months after initiation of LAI-SGAs. We also performed multiple regression analysis to explore factors associated with change in total daily dose 12 months after treatment initiation. A total of 154 patients fulfilled the inclusion criteria. There was no significant difference in total daily antipsychotic dose between 3 months and 12, 24 or 36 months after treatment initiation. Total daily dose was increased in 43 (27.9%), 31 (34.8%) and 22 patients (36.7%) at 12, 24 and 36 months, respectively. Age and total antipsychotic dose at 3 months were significantly negatively associated with change in total daily dose. Antipsychotic dose was basically unchanged during long-term treatment in patients treated with LAI-SGAs in the maintenance phase, although there was an increase in some patients.

UI MeSH Term Description Entries
D007267 Injections Introduction of substances into the body using a needle and syringe. Injectables,Injectable,Injection
D008137 Longitudinal Studies Studies in which variables relating to an individual or group of individuals are assessed over a period of time. Bogalusa Heart Study,California Teachers Study,Framingham Heart Study,Jackson Heart Study,Longitudinal Survey,Tuskegee Syphilis Study,Bogalusa Heart Studies,California Teachers Studies,Framingham Heart Studies,Heart Studies, Bogalusa,Heart Studies, Framingham,Heart Studies, Jackson,Heart Study, Bogalusa,Heart Study, Framingham,Heart Study, Jackson,Jackson Heart Studies,Longitudinal Study,Longitudinal Surveys,Studies, Bogalusa Heart,Studies, California Teachers,Studies, Jackson Heart,Studies, Longitudinal,Study, Bogalusa Heart,Study, California Teachers,Study, Longitudinal,Survey, Longitudinal,Surveys, Longitudinal,Syphilis Studies, Tuskegee,Syphilis Study, Tuskegee,Teachers Studies, California,Teachers Study, California,Tuskegee Syphilis Studies
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012559 Schizophrenia A severe emotional disorder of psychotic depth characteristically marked by a retreat from reality with delusion formation, HALLUCINATIONS, emotional disharmony, and regressive behavior. Dementia Praecox,Schizophrenic Disorders,Disorder, Schizophrenic,Disorders, Schizophrenic,Schizophrenias,Schizophrenic Disorder
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major

Related Publications

Nozomi Nakajima, and Nao Mizoe, and Fuminari Misawa, and Toru Yamashita, and Ryuhei So, and Kohei Kitagawa, and Kenichi Tanimoto, and Yoshiki Kishi, and Yasuo Fujii, and Hiroyoshi Takeuchi
January 2022, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova,
Nozomi Nakajima, and Nao Mizoe, and Fuminari Misawa, and Toru Yamashita, and Ryuhei So, and Kohei Kitagawa, and Kenichi Tanimoto, and Yoshiki Kishi, and Yasuo Fujii, and Hiroyoshi Takeuchi
March 2018, Schizophrenia research,
Nozomi Nakajima, and Nao Mizoe, and Fuminari Misawa, and Toru Yamashita, and Ryuhei So, and Kohei Kitagawa, and Kenichi Tanimoto, and Yoshiki Kishi, and Yasuo Fujii, and Hiroyoshi Takeuchi
September 2012, Drug and therapeutics bulletin,
Nozomi Nakajima, and Nao Mizoe, and Fuminari Misawa, and Toru Yamashita, and Ryuhei So, and Kohei Kitagawa, and Kenichi Tanimoto, and Yoshiki Kishi, and Yasuo Fujii, and Hiroyoshi Takeuchi
July 2013, Expert review of neurotherapeutics,
Nozomi Nakajima, and Nao Mizoe, and Fuminari Misawa, and Toru Yamashita, and Ryuhei So, and Kohei Kitagawa, and Kenichi Tanimoto, and Yoshiki Kishi, and Yasuo Fujii, and Hiroyoshi Takeuchi
March 2018, CNS drugs,
Nozomi Nakajima, and Nao Mizoe, and Fuminari Misawa, and Toru Yamashita, and Ryuhei So, and Kohei Kitagawa, and Kenichi Tanimoto, and Yoshiki Kishi, and Yasuo Fujii, and Hiroyoshi Takeuchi
January 2019, The mental health clinician,
Nozomi Nakajima, and Nao Mizoe, and Fuminari Misawa, and Toru Yamashita, and Ryuhei So, and Kohei Kitagawa, and Kenichi Tanimoto, and Yoshiki Kishi, and Yasuo Fujii, and Hiroyoshi Takeuchi
April 1994, American journal of hospital pharmacy,
Nozomi Nakajima, and Nao Mizoe, and Fuminari Misawa, and Toru Yamashita, and Ryuhei So, and Kohei Kitagawa, and Kenichi Tanimoto, and Yoshiki Kishi, and Yasuo Fujii, and Hiroyoshi Takeuchi
March 2019, International clinical psychopharmacology,
Nozomi Nakajima, and Nao Mizoe, and Fuminari Misawa, and Toru Yamashita, and Ryuhei So, and Kohei Kitagawa, and Kenichi Tanimoto, and Yoshiki Kishi, and Yasuo Fujii, and Hiroyoshi Takeuchi
September 2019, International journal of psychiatry in clinical practice,
Nozomi Nakajima, and Nao Mizoe, and Fuminari Misawa, and Toru Yamashita, and Ryuhei So, and Kohei Kitagawa, and Kenichi Tanimoto, and Yoshiki Kishi, and Yasuo Fujii, and Hiroyoshi Takeuchi
December 2018, Therapeutic advances in psychopharmacology,
Copied contents to your clipboard!